Alternative end-joining in BCR gene rearrangements and translocations

Bai, Wanyu; Zhao, Bo; Gu, Mingyu; Dong, Jing

doi:10.3724/abbs.2022051

Cited by 3 publications

(1 citation statement)

References 157 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In cellular DNA repair mechanisms, two primary forms are involved in addressing double-strand breaks (DSBs): homologous recombination repair (HR) and nonhomologous end-joining repair (NHEJ) [15] . In recent years, there has been significant progress in the comprehension of alternative end-joining (A-EJ), not only as an alternative pathway to classical end-joining (c-NHEJ) but also as a potential competitor for DSB repair alongside c-NHEJ [16] . The most genotoxic form of DNA damage is represented by DSBs, as they exert an impact on the precise segregation of chromosomes during cellular division [17] .…”

Section: Mechanisms Of Ddr In Regulating Crcmentioning

confidence: 99%

Advances in DNA damage response inhibitors in colorectal cancer therapy

Yu,

Jia,

Zhang

et al. 2023

ABBS

View full text Add to dashboard Cite

One potential cause of cancer is genomic instability that arises in normal cells due to years of DNA damage in the body. The clinical application of radiotherapy and cytotoxic drugs to treat cancer is based on the principle of damaging the DNA of cancer cells. However, the benefits of these treatments also have negative effects on normal tissue. While there have been notable advancements in molecular-driven therapy and immunotherapy for colorectal cancer (CRC), a considerable portion of patients with advanced CRC do not experience any benefits from these treatments, leading to a poor prognosis. In recent years, targeted therapy aimed at suppressing the DNA damage response (DDR) in cancer cells has emerged as a potential treatment option for CRC patients, offering them more choices for treatment. Currently, the integration of DDR and clinical intervention remains in the exploratory phase. This review primarily elucidates the fundamental principles of DDR inhibitors, provides an overview of their current clinical application status in CRC, and discusses the advancements as well as limitations observed in relevant studies.

show abstract

Section: Mechanisms Of Ddr In Regulating Crcmentioning

confidence: 99%

Advances in DNA damage response inhibitors in colorectal cancer therapy

Yu,

Jia,

Zhang

et al. 2023

ABBS

View full text Add to dashboard Cite

show abstract

Immunoglobulin class‐switch recombination: Mechanism, regulation, and related diseases

Liu,

Zhang,

Zhang

et al. 2024

MedComm

View full text Add to dashboard Cite

Maturation of the secondary antibody repertoire requires class‐switch recombination (CSR), which switches IgM to other immunoglobulins (Igs), and somatic hypermutation, which promotes the production of high‐affinity antibodies. Following immune response or infection within the body, activation of T cell‐dependent and T cell‐independent antigens triggers the activation of activation‐induced cytidine deaminase, initiating the CSR process. CSR has the capacity to modify the functional properties of antibodies, thereby contributing to the adaptive immune response in the organism. Ig CSR defects, characterized by an abnormal relative frequency of Ig isotypes, represent a rare form of primary immunodeficiency. Elucidating the molecular basis of Ig diversification is essential for a better understanding of diseases related to Ig CSR defects and could provide clues for clinical diagnosis and therapeutic approaches. Here, we review the most recent insights on the diversification of five Ig isotypes and choose several classic diseases, including hyper‐IgM syndrome, Waldenström macroglobulinemia, hyper‐IgD syndrome, selective IgA deficiency, hyper‐IgE syndrome, multiple myeloma, and Burkitt lymphoma, to illustrate the mechanism of Ig CSR deficiency. The investigation into the underlying mechanism of Ig CSR holds significant potential for the advancement of increasingly precise diagnostic and therapeutic approaches.

show abstract

Install, repair and outcomes: a special issue on physiological and programmed DNA lesions

Meng¹

2022

ABBS

View full text Add to dashboard Cite

Alternative end-joining in BCR gene rearrangements and translocations

Cited by 3 publications

References 157 publications

Advances in DNA damage response inhibitors in colorectal cancer therapy

Advances in DNA damage response inhibitors in colorectal cancer therapy

Immunoglobulin class‐switch recombination: Mechanism, regulation, and related diseases

Install, repair and outcomes: a special issue on physiological and programmed DNA lesions

Contact Info

Product

Resources

About